SHO is set to sell the Hyatt Regency San Francisco to a Blackstone fund for $279M as it redeploys proceeds through share buybacks and weighs further uses.
Dan Oneglia, liquid-credit strategist, called the capping mechanism a “feature and not a flaw” of the structure.
Blackstone is planning to invest $30 billion in Japan's artificial intelligence data centers over the next three to five years, its president and chief operating officer Jonathan Gray told Nikkei in a recent interview, the business daily reported on Tuesday.
The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between June 5 and June 11. This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities. Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.
Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company's IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotechnology equity research analyst Salveen Richter.
Blackstone Inc. (BX) is rated a Buy, offering quality growth at discounted valuations despite sector-wide private credit concerns. BX's diversified model, robust credit underwriting, and focus on investment-grade secured debt position it to absorb private credit shocks better than peers. Key growth catalysts in AI/data center infrastructure, 401(k) regulatory changes, and perpetual capital, are not fully priced into BX shares.
Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript
BX's stock price has recently dropped by nearly 40%. And it left investors wondering whether it's time to sell or buy even more. BX's fundamentals don't justify the sell-off, as its inflows, fee growth, AUM, and other key metrics were either record-level or very strong. The market is wrong about BX being a victim of AI. In fact, it's one of the beneficiaries.
Blackstone restricts flagship fund withdrawals as private asset fears reemerge
Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.
The New York-based alternative asset manager raised more than the $10 billion target for the Blackstone Capital Partners Asia III fund.
Apollo Global Management and Blackstone are working to bring in additional investors for about $36 billion debt financing tied to AI startup Anthropic PBC's efforts to expand its AI infrastructure, Bloomberg News reported on Thursday.